In a foregoing paper (1), a method for labeling histamine H1 receptor with radioactive dibenamine in the smooth muscle of cat small intestine was proposed. We found 7 p moles bound dibenamine per mg protein of the total tissue homogenate and 40 p moles per mg protein of the plasma membrane fraction. This communication deals with reconsideration on the receptor specificity of this bound dibenamine or, more accurately, on the selectivity of H1 receptor. The procedure in the previous paper (1) involved `double protection' which means the two-step application of protectors against dibenamine : the first protection was the usual one with protective antihistamine, promethazine, and the second was cross pro tection of non-specific sites with drugs having negligible antihistaminic actions in the doses used, thioridazine and atropine. Muscle strips protected with promethazine against non radioactive dibenamine were treated with 3H-dibenamine in the presence of these second protectors. The second protectors were to cover non-specific sites which had been protected non-specifically with promethazine from non-radioactive dibenamine. The first non radioactive dibenamine was 4 times higher in concentration than the second 3H-dibenamine.
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The difficulty is in determining the proportion of non-specific sites labeled with 3H dibenamine presumed to represent receptor-specific binding, as reported previously (2) . This problem arises from the non-saturable mode of binding of dibenamine to the tissue.
Moran et al. (3) reported that new nucleophilic groups were successively uncovered to react with dibenamine after dibenamine had bound to those groups already present. In our method, 3H-dibenamine is considered to bind to the newly uncovered groups even after non-radioactive dibenamine reacts with the non-receptor sites already present. To assess non-receptor binding of 3H-dibenamine, 3H-dibenamine (1 x 10-6 M, whose concentration was sufficient to suppress histamine-induced contraction in our preparations) was applied in the presence of promethazine (3 x 10-1 M), thioridazine (3 x 10-' M) and atropine (3 x 10-7 M) after application of non-radioactive dibenamine (4 x 10-6 M) under protection with promethazine (3 x 10-7 M) as shown in Fig. 1-A . The radioactivity of bound 3H-dibenamine was compared to the sample from the same cat labeled in the presence of thioridazine and atropine but without promethazine as shown in Fig. 1-B . Thioridazine and atropine did not protect the histamine H1 receptor under these conditions, however protection was evident with promethazine.
The labeled muscle strips were homogenized and fractionated as described previously (4). 3H-Dibenamine (58.5 Ci/mole) was prepared as already reported Small intestines were removed and the longiutudinal layer of smooth muscle was carefully peeled off. Procedure A was for labeling non-receptor sites which were uncovered after unlabeled dibenamine had bound to non-receptor sites already present. Procedure B was for labeling both receptor sites and non-receptor sites. Thus the difference between the two procedures will represent the receptor label whose proportion to non-receptor ones is now under investigation.
The results are shown in Table 1 to using radioactive dibenamine. However, such do provide a criterion for further fractio nation of labeled materials or for another trial to label H1 receptor with a more selective alkylator. For example, diphenhydramine mustard (9) has about a 7-fold higher affinity for H1 receptor than dibenamine whose apparent affinity for H1 receptor after 20 min in cubation is about 1/40 of mepyramine.
